These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20497749)

  • 1. Critical questions concerning the validity of the Bayer study report of "Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration".
    Meyer MC
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):405-11; author reply 412-5, 416-8. PubMed ID: 20497749
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.
    Anschütz M; Wonnemann M; Schug B; Toal C; Donath F; Pontius A; Pauli K; Brendel E; Blume H
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):158-70. PubMed ID: 20137768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutically relevant blood pressure differences with two nifedipine (60 mg) osmotic delivery systems of differing design: three case reports.
    Pollak PT
    Int J Clin Pharmacol Ther; 2010 Jun; 48(6):400-4. PubMed ID: 20497748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sandwiched osmotic tablet core for nifedipine controlled delivery.
    Liu L; Khang G; Rhee JM; Lee HB
    Biomed Mater Eng; 1999; 9(5-6):297-310. PubMed ID: 10822485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioequivalence of nifedipine sustained-release formulations in comparison to standard preparations in solid state].
    Herrmann R
    Arzneimittelforschung; 1996 Jan; 46(1):28-34. PubMed ID: 8821514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques.
    Liu X; Wang S; Chai L; Zhang D; Sun Y; Xu L; Sun J
    Int J Pharm; 2014 Jan; 461(1-2):529-39. PubMed ID: 24374219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unitary-core osmotic pump tablet for controlled release of water-insoluble drug].
    Liu LX; Xu Q; Khang G; Rhee JM; Lee HB
    Yao Xue Xue Bao; 2003 Dec; 38(12):966-7. PubMed ID: 15040097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers.
    Melia AT; Mulligan TE; Zhi J
    J Clin Pharmacol; 1996 Apr; 36(4):352-5. PubMed ID: 8728349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability study of two nifedipine tablet formulations in healthy male volunteers.
    Niopas I; Daftsios AC; Xanthakis I; Nikolaidis N
    Int J Clin Pharmacol Ther; 2000 Jun; 38(6):309-14. PubMed ID: 10890580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bioavailability of experimental controlled release microcapsules of nifedipine.
    Mallick S; Gupta BK; Ghosal SK
    Acta Pol Pharm; 2000; 57(3):175-80. PubMed ID: 11143705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative human pharmacokinetic studies of 20 mg nifedipine-containing Cordaflex and Adalat film coated retared tablets].
    Klebovich I; Horvai G; Grézal G; Baloghné NK; Horváth V; Kocsi E; Balogh J; Cseh A; Farsang C
    Acta Pharm Hung; 1996 Jan; 66(1):29-39. PubMed ID: 8714363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differences in the bioavailability of delayed action and standard preparations of calcium antagonists].
    Blume H
    Internist (Berl); 1994 Aug; 35(8):782-3. PubMed ID: 7960558
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of nifedipine in human plasma and its use in bioequivalence study.
    Guo Y; Dai J; Qian G; Guo N; Ma Z; Guo X
    Int J Pharm; 2007 Aug; 341(1-2):91-6. PubMed ID: 17507190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.
    Abrahamsson B; Alpsten M; Bake B; Jonsson UE; Eriksson-Lepkowska M; Larsson A
    J Control Release; 1998 Mar; 52(3):301-10. PubMed ID: 9743450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine preparations on the Belgian market: a comparative study.
    De Braekeleer K; Fierens C; Corthout J
    J Pharm Belg; 2009 Dec; (4):141-6. PubMed ID: 20183991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of nifedipine lipospheres.
    Vyas SP; Singh R; Dimitrijevic D
    Pharmazie; 1997 May; 52(5):403-4. PubMed ID: 9183794
    [No Abstract]   [Full Text] [Related]  

  • 18. Monolithic osmotic tablet system for nifedipine delivery.
    Liu L; Khang G; Rhee JM; Lee HB
    J Control Release; 2000 Jul; 67(2-3):309-22. PubMed ID: 10825563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifedipine in ischemic heart disease.
    Kloner RA
    Circulation; 1995 Sep; 92(5):1074-8. PubMed ID: 7648647
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of coated nifedipine dry elixir as a long acting oral delivery with bioavailability enhancement.
    Choi JY; Jin SE; Park Y; Lee HJ; Park Y; Maeng HJ; Kim CK
    Arch Pharm Res; 2011 Oct; 34(10):1711-7. PubMed ID: 22076771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.